Constitutional Symptoms Masking COVID-19 In A Patient with Primary Myelofibrosis
Annals of Clinical and Medical Case Reports · 2020
DOI: 10.47829/acmcr.2020.41001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Clinical and Medical Case Reports, 2020. Verfasst von Khan M und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Constitutional symptoms of primary myelofibrosis can mask COVID-19 infection. We present the case of a patient with primary myelofibrosis on ruxolitinib who tested positive for COVID-19 as part of Hematopoietic Stem Cell Transplant (HSCT) workup. The patient was asymptomatic and took over four weeks to develop a negative COVID-19 RT-PCR test. She did not test positive for COVID-19 antibodies. Patients with hematologic malignancies such as primary myelofibrosis or patients taking immunosuppressive therapy, such as ruxolitinib, may not develop infectious symptoms from COVID-19. In addition, they may take longer to test negative and may not develop antibodies to COVID-19. Therefore, these patients may be more vulnerable to re-infection. Although ruxolitinib may contribute to immunosuppression and increased susceptibility to infection, the drug is being studied as a possible treatment for COVID-19. To improve safety and patient outcomes, it is critical to test patients for COVID-19 prior to HSCT as clinicians cannot rely on symptoms to determine infection.
Zitieren
APA
M, K., C, S., & D, R. (2020). Constitutional Symptoms Masking COVID-19 In A Patient with Primary Myelofibrosis. Annals of Clinical and Medical Case Reports. https://doi.org/10.47829/acmcr.2020.41001
Vancouver
M K, C S, D R. Constitutional Symptoms Masking COVID-19 In A Patient with Primary Myelofibrosis. Annals of Clinical and Medical Case Reports. 2020. doi:10.47829/acmcr.2020.41001
BibTeX
@article{M2020,
author = {M, Khan and C, Schwartz and D, Rondelli},
title = {Constitutional Symptoms Masking COVID-19 In A Patient with Primary Myelofibrosis},
journal = {Annals of Clinical and Medical Case Reports},
year = {2020},
doi = {10.47829/acmcr.2020.41001}
}
EUVIMED